The Digital Therapeutics Report: The Teladoc-Livongo megamerger put a spotlight on the power of digital therapies—here are the most innovative players racing to catch up as the pandemic vaults the market to reach $56 billion by 2025

The Digital Therapeutics Report: The Teladoc-Livongo megamerger put a spotlight on the power of digital therapies—here are the most innovative players racing to catch up as the pandemic vaults the market to reach $56 billion by 2025

Regular price
$995.00
Sale price
$995.00
Already a PRO customer? Log in to read all reports.

Digital therapeutics (DTx) were gaining popularity as tools to help slash the US’ $3 trillion annual spending on chronic disease, and the pandemic has vaulted digital therapies into the spotlight. Now, the Teladoc-Livongo megamerger is heating up competition in the DTx space as players race to capture a slice of a market slated to reach $56 billion by 2025.

Report License & Terms of Use: eMarketer grants a non-exclusive, individual license to the named user ("Licensee") to view and use the Report(s). Licensee acknowledges that all copyright, patent and other intellectual property rights to the Report(s) are owned by, and remain vested in, eMarketer. Licensee may excerpt, paraphrase, or quote up to 100 words and 5 charts from any single report, provided that the eMarketer copyright notice is affixed thereto, and that the Licensee does not modify or otherwise alter the general impressions of the Report(s), and does not imply sponsorship, approval, or endorsement by eMarketer.